Liquid Biopsy Early Cancer Detection Monitoring Market Trends, Share, and Growth Analysis 2035
The liquid biopsy early cancer detection and monitoring market is forecasted to expand from USD 2.99 billion in 2026 to USD 9.28 billion by 2035, growing at a CAGR of 13.40% from 2026 to 2035.
Key Takeaways
Market Size & Growth Outlook
- Market size in 2025: USD 2.64 billion
- Estimated market size in 2026: USD 2.99 billion
- Projected market size by 2035: USD 9.28 billion
- CAGR (2026-2035): 13.40%
Regional Market Spotlight
- North America led the market with a 54.60% (USD 1.44 billion) share in 2025.
- Europe accounted for 21.80% (USD 0.58 billion) of the market in 2025.
- Asia Pacific accounted for 19.20% (USD 0.51 billion) of the market in 2025 and is projected to be the fastest-growing region, at a CAGR of 15.20% from 2025 to 2035.
Segmental Spotlight
- By biomarker, Circulating Tumor DNA accounted for 64.20% (USD 1.69 billion) in 2025.
- By technology, NGS accounted for 52.60% (USD 1.39 billion) in 2025.
- By application, Early Detection & Screening accounted for 44.60% (USD 1.18 billion) in 2025.
- By cancer type, Multi-cancer & Others accounted for 25.00% (USD 0.66 billion) in 2025.
Liquid Biopsy Early Cancer Detection Monitoring Market Size and Forecast, 2025-2035 (USD Billion)
Note: 2025 is the base year; 2026-2035 values are forecasts.
Sources: Expert interviews, secondary sources, Precedence Research database and Precedence Research analysts.
The liquid biopsy early cancer detection and monitoring market is projected to grow from USD 2.64 billion in 2025 to USD 9.28 billion by 2035 because patients and clinicians adopt blood tests for colorectal and multi-cancer screening and use ctDNA tests to detect residual disease and recurrence after treatment. The creation of new Medicare coverage options and regulatory filings for multi-cancer screening tests would make the product more acceptable and drive the market to reach USD 4.95 billion by 2030 at a CAGR of 13.40%.
- Analyst View: The calculation was based on volumes for blood-based screening, MRD, and monitoring tests, by type of cancer and geographic region, multiplied by the average price per test paid to laboratories and patient self-pay amounts. Volumes include test quantities from key firms, Medicare reimbursement for MRD testing in multiple cancers, and the adoption of tests through both the clinical and consumer markets. We cross-checked the total against the screening and monitoring revenue of leading liquid biopsy companies and published estimates, which places our base year slightly above comparable figures. Growth rate depends on the extent of coverage and evidence from clinical trials, but also on different test results and the time needed for the approval of multi-cancer tests.
Market Trends
- Multi-cancer early detection tests are moving toward FDA approval.
- Medicare legislation creates a coverage pathway for multi-cancer screening.
- Tumor-informed MRD tests guide adjuvant therapy.
- Methylation signals identify both cancer presence and origin.
- Consumer health platforms offer screening tests.
- Blood tests are becoming an option for colorectal screening.
Drivers, Restraints and Opportunities
Driver
Many cancers are found late, and blood tests offer a simple way to detect cancer earlier and to screen for cancers without existing screening programs. New federal legislation creates a Medicare pathway for multi-cancer early detection tests. MRD testing can help oncologists determine if their patients require additional treatment and in the case of recurrence. There is a new FDA-approved blood test for colorectal cancer screening. The test becomes more accessible with reduced sequencing costs.
Restraint
The clinical data on multi-cancer testing are yet to mature, and the NHS-Galleri trial failed to hit the target point. Sensitivity to early cancer stages is still not high enough. Tests are expensive, and many are paid out of pocket. There are chances of false positives, resulting in unnecessary worries and additional costs. Large-scale clinical trials are essential for the clearance of screening procedures.
Opportunity
FDA approval of multi-cancer tests and Medicare coverage could create a very large screening opportunity. MRD testing can expand to more cancer types and become standard of care. Combining ctDNA, proteins, and AI might increase accuracy levels. Both consumer and employer delivery channels would allow for broadening of access. There is great potential for development in Asia's cancer market.
Market Segmentation: 2025 Share and Value
Liquid Biopsy Early Cancer Detection Monitoring Market by Biomarker 2025 Share
Note: 2025 is the base year.
Sources: Expert interviews, secondary sources, Precedence Research database and Precedence Research analysts.
Circulating tumor DNA accounted for 64.20% (USD 1.69 billion) in 2025 because ctDNA mutations and methylation signals are the basis of most multi-cancer screening, colorectal blood screening, and tumor-informed MRD tests. With sensitive sequencing, very small quantities of tumor DNA may be identified following surgery. Circulating tumor cells, at 14.60% (USD 0.39 billion), are used for prognosis and monitoring in breast and prostate cancer; circulating proteins and other markers account for 11.80% (USD 0.31 billion), often combined with ctDNA to improve accuracy; and exosomes and microvesicles account for 9.40% (USD 0.25 billion), mainly in development.
Liquid Biopsy Early Cancer Detection Monitoring Market by Technology 2025 Share & Size
| Segments | 2025 Share | 2025 Market Value |
| NGS | 52.60% | USD 1.39 billion |
| PCR-based Assays | 22.40% | USD 0.59 billion |
| Methylation Assays | 14.80% | USD 0.39 billion |
| Microarray & Others | 10.20% | USD 0.27 billion |
Note: 2025 is the base year.
Sources: Expert interviews, secondary sources, Precedence Research database and Precedence Research analysts.
NGS accounted for 52.60% (USD 1.39 billion) in 2025 because it can detect many mutations and fragments at once and supports both tumor-informed MRD and multi-cancer methylation tests. PCR-based assays, at 22.40% (USD 0.59 billion), including digital PCR, offer low-cost monitoring of known mutations; methylation assays account for 14.80% (USD 0.39 billion) and are the fastest-growing technology because methylation patterns can identify both the presence and origin of cancer; and microarray and other methods account for 10.20% (USD 0.27 billion).
Liquid Biopsy Early Cancer Detection Monitoring Market by Application 2025 Share
Note: 2025 is the base year.
Sources: Expert interviews, secondary sources, Precedence Research database and Precedence Research analysts.
Early detection and screening accounted for 44.60% (USD 1.18 billion) in 2025 and is the fastest-growing application, supported by the FDA-approved blood test for colorectal cancer screening and a new Medicare coverage pathway. MRD and recurrence monitoring, at 36.20% (USD 0.96 billion), helps oncologists decide on adjuvant therapy and detect relapse earlier, and therapy response monitoring accounts for 19.20% (USD 0.51 billion).
Liquid Biopsy Early Cancer Detection Monitoring Market by Cancer Type 2025 Share & Size
| Segments | 2025 Share | 2025 Market Value |
| Multi-cancer & Others | 25.00% | USD 0.66 billion |
| Lung Cancer | 24.80% | USD 0.65 billion |
| Colorectal Cancer | 22.60% | USD 0.60 billion |
| Breast Cancer | 18.40% | USD 0.49 billion |
| Prostate Cancer | 9.20% | USD 0.24 billion |
Note: 2025 is the base year.
Sources: Expert interviews, secondary sources, Precedence Research database and Precedence Research analysts.
Multi-cancer and other cancers accounted for 25.00% (USD 0.66 billion) in 2025, reflecting multi-cancer early detection tests that screen for dozens of cancer types. Lung cancer, at 24.80% (USD 0.65 billion), uses ctDNA for monitoring and early detection research; colorectal cancer accounts for 22.60% (USD 0.60 billion) and leads MRD and blood screening use; breast cancer accounts for 18.40% (USD 0.49 billion); and prostate cancer for 9.20% (USD 0.24 billion).
- Analyst View: Segment values were allocated by matching test volumes by application and cancer type to biomarkers and technologies, using average prices. ctDNA and NGS lead because they underpin most commercial tests. These tests are expected to occupy more space in the market because of the expanded scope of their coverage and approval.
Regional Analysis
Liquid Biopsy Early Cancer Detection Monitoring Market by Region 2025 Share
Note: 2025 is the base year.
Sources: Expert interviews, secondary sources, Precedence Research database and Precedence Research analysts.
North America accounted for 54.60% (USD 1.44 billion) in 2025, growing on commercial multi-cancer and colorectal blood tests, Medicare coverage for MRD tests in several cancers, federal legislation creating a Medicare pathway for multi-cancer early detection, and consumer access through telehealth platforms. Europe, at 21.80% (USD 0.58 billion), is supported by large screening trials such as NHS-Galleri in England, MRD research and growing liquid biopsy use in Germany, France, and the Netherlands. Asia Pacific, at 19.20% (USD 0.51 billion), is the fastest-growing region, supported by Chinese liquid biopsy companies developing methylation-based screening tests, high cancer burdens, and expanding precision oncology in Japan and South Korea. Latin America, at 2.60% (USD 0.07 billion), and the Middle East and Africa, at 1.80% (USD 0.05 billion), are small markets where tests are mainly offered by private laboratories and international providers.
North America accounted for 54.60% (USD 1.44 billion) in 2025. Commercial screening and MRD tests drive the market. Medicare coverage supports MRD testing. A new law creates a Medicare pathway for multi-cancer tests.
Europe accounted for 21.80% (USD 0.58 billion) in 2025. Large screening trials in England test multi-cancer detection. MRD research is strong. Reimbursement is still limited.
Asia Pacific accounted for 19.20% (USD 0.51 billion) in 2025 and is the fastest-growing region. Chinese companies are developing methylation screening tests. Asia Pacific market is growing due to the rising prevalence of cancer. Japan and South Korea are expanding precision oncology.
Latin America accounted for 2.60% (USD 0.07 billion) in 2025. Liquid biopsies can be done in private labs. They are not widely available.
The Middle East and Africa accounted for 1.80% (USD 0.05 billion) in 2025. Gulf centers offer international tests. Adoption is at an early stage.
Analyst View: Regional shares were built from screening and monitoring test volumes, coverage, and prices in each region. North America leads because of commercial launches and Medicare coverage. The Asia Pacific region is assigned the largest growth premium due to the presence of local methylation-based screening firms and high incidences of cancer.
Top 10 Companies in the Liquid Biopsy Early Cancer Detection Monitoring Market
| Rank | Company Name | Market-Specific Revenue (USD Billion) | 2025 Share | Key Products/Business | Headquarters |
| 1 | Natera | 0.48 | 18.18% | Signatera tumour-informed MRD tests | United States |
| 2 | Guardant Health | 0.38 | 14.39% | Shield colorectal screening and Guardant Reveal MRD tests | United States |
| 3 | Exact Sciences | 0.24 | 9.09% | Oncodetect MRD and blood-based screening tests | United States |
| 4 | Roche (Foundation Medicine) | 0.18 | 6.82% | FoundationOne Tracker and liquid biopsy tests | Switzerland |
| 5 | GRAIL | 0.15 | 5.68% | Galleri multi-cancer early detection test | United States |
| 6 | Burning Rock Biotech | 0.06 | 2.27% | Methylation-based cancer detection tests | China |
| 7 | Myriad Genetics | 0.06 | 2.27% | Precise MRD tests | United States |
| 8 | Bio-Rad Laboratories | 0.05 | 1.89% | Droplet digital PCR for ctDNA monitoring | United States |
| 9 | Freenome | 0.04 | 1.52% | Blood-based colorectal screening test | United States |
| 10 | Personalis | 0.04 | 1.52% | NeXT Personal MRD test | United States |
Note: Company revenues and shares are 2025 estimates.
Sources: Company press releases, expert interviews, secondary sources, Precedence Research database and Precedence Research analysts.
Natera led the liquid biopsy early cancer detection and monitoring market with an estimated 18.18% (USD 0.48 billion) of 2025 revenue, followed by Guardant Health at 14.39% (USD 0.38 billion) and Exact Sciences at 9.09% (USD 0.24 billion). Natera leads MRD testing with Signatera, a tumor-informed ctDNA test covered by Medicare for several cancers and used widely after surgery. Guardant Health leads blood-based colorectal cancer screening with the FDA-approved Shield test and offers Guardant Reveal for recurrence monitoring. Exact Sciences is expanding from stool-based screening into MRD and blood-based detection, GRAIL leads multi-cancer early detection with Galleri, which sold more than 185,000 tests in 2025 and has completed its FDA approval submission; and Roche, Myriad, Personalis, Freenome, Burning Rock, and Bio-Rad add MRD, screening, and digital PCR products.
Top 10 firms constituted about 63.64% (USD 1.68 billion) of revenue in 2025, whereas the balance of 36.36% (USD 0.96 billion) comprised liquid biopsy startups, methylation test providers in China, academic labs, and assay providers. The liquid biopsy early cancer detection and monitoring market is moderately concentrated among a few U.S. companies, and competition centers on clinical sensitivity and specificity, published evidence, regulatory approvals, Medicare and payer coverage, and access channels. Future competitiveness within the forecasted period will be determined by clinical trials and FDA approvals for multi-cancer tests.
Recent Developments
- February 2026: In its financial report of 2025, GRAIL reported sales of more than 185,000 units of Galleri test and mentioned that the "Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act" has been passed into law.
Liquid Biopsy Early Cancer Detection Monitoring Market Segments
By Biomarker
- Circulating Tumor DNA
- Circulating Tumor Cells
- Circulating Proteins & Others
- Exosomes & Microvesicles
By Technology
- NGS
- PCR-based Assays
- Methylation Assays
- Microarray & Others
By Application
- Early Detection & Screening
- MRD & Recurrence Monitoring
- Therapy Response Monitoring
By Cancer Type
- Multi-cancer & Others
- Lung Cancer
- Colorectal Cancer
- Breast Cancer
- Prostate Cancer
By Region
- North America (U.S., Canada, Mexico)
- Europe (Germany, U.K., France, Italy, Spain, Rest of Europe)
- Asia Pacific (China, Japan, India, South Korea, Taiwan, Rest of Asia Pacific)
- Latin America (Brazil, Argentina, Rest of Latin America)
- Middle East & Africa (GCC, South Africa, Rest of MEA)
Research Methodology
The liquid biopsy early cancer detection and monitoring market refers to blood-based tests using ctDNA, methylation, exosomes, and proteins for cancer screening, early detection, MRD, and monitoring worldwide. The 2025 base year was built bottom-up from screening, MRD, and monitoring test volumes by cancer type and region and average test prices, and checked top-down against the screening and monitoring revenue of leading liquid biopsy companies. Segment, regional, and company values were allocated from biomarkers, technologies, applications, cancer types, and regional testing. Key estimates were verified by cross-checking company disclosures, regulatory and industry data and published third-party estimates, and inputs that could not be reconciled were excluded. All segment, regional, and company figures were reconciled to the same 2025 base year, and the 2026-2035 forecast, which applies a constant CAGR from the 2025 base, was recalculated and validated.
Analyst View: Overall Market
The liquid biopsy early cancer detection and monitoring market is at an important stage, with MRD testing growing quickly and multi-cancer screening approaching regulatory and coverage milestones. Our estimates connect demand with testing and surveillance, which means our forecasts track the scientific data and approvals. The main upside comes from multi-cancer test approval, Medicare coverage and MRD adoption, while the main risks are mixed trial results and high test costs.
Sources and References
- GRAIL. "GRAIL reports fourth quarter and full year 2025 financial results". 2026-02-19. Galleri tests, PMA submission and Medicare law. https://grail.com/press-releases/grail-reports-fourth-quarter-and-full-year-2025-financial-results/
- GRAIL. "GRAIL submits FDA premarket approval application for the Galleri multi-cancer early detection test". 2026-01. Galleri PMA submission. https://grail.com/?p=7606
For inquiries regarding discounts, bulk purchases, or customization requests, please contact us at sales@precedenceresearch.com
Frequently Asked Questions
Ask For Sample
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Get a Sample
Report Description
Get a Sample
sales@precedenceresearch.com
Schedule a Meeting